Ingredient intelligence report
Ingredient hub · not a branded product review
Verdict
Studies conflict or are small; some plausible benefits, but the signal is too noisy for strong claims.
Last updated: 2026年4月25日
Overall
Trust score summarizes evidence, safety, and hype gap in our fixed rubric - not a personal recommendation.
Best for
Six editorial checks applied to every published hub. Status reflects our fixed scoring bands, not a product lab test.
Human data exist but are uneven, narrow, or contested for the loudest claims.
Dosage discussion is documented on this hub; compare any bottle to studied ranges yourself.
Some gap between marketing certainty and trial endpoints remains visible.
This page is an ingredient hub (not a SKU review). Transparency is judged at the evidence-and-claim level, not for a single brand label.
Evidence is partial, industry-skewed, or not yet convincing at scale.
Fewer prominent red flags in conventional-use discussions - still not individualized risk clearance.
Formula
Human data quality varies by indication and extract. Registry evidence tier: medium. Use the evidence score on this page as a directional read, not a substitute for systematic reviews for your specific question.
Synapsa (Bacopa CDRI-08)
Listed dose (hub)
See dosage notes (varies by product)
Some human data exist, but trials are small, heterogeneous, or not aligned with popular claims.
Why it matters
Retail products vary by salt form, dose, and purity. The hub anchors what the compound can claim in evidence - not every bottle on the shelf.
Credibility
Editorial read of marketing narratives versus trial support and safety context. Not a regulatory finding.
Typical storefront and social narratives versus what human data actually test.
Where messaging tends to outrun endpoints, populations, or replication in trials.
Economics
Ingredient hubs are not pegged to a single SKU or live price feed. The read below ties value posture to evidence and hype - not checkout data.
Context-only valuation
Context-only read
No single retail price is evaluated here. Use evidence and hype signals to judge whether branded premiums are justified.
Higher overall score with equal or lower hype gap in our model - navigation hints, not medical advice or guaranteed substitutes.
Some links elsewhere on the site may earn a commission. Rankings and scores are not influenced by affiliate relationships.
Stronger composite score with contained hype versus Synapsa (Bacopa CDRI-08) in this dataset.
Stronger composite score with contained hype versus Synapsa (Bacopa CDRI-08) in this dataset.
Stronger composite score with contained hype versus Synapsa (Bacopa CDRI-08) in this dataset.
Short answers for search intent. The analysis sections above carry the full nuance.
Literature
Human data quality varies by indication and extract. Registry evidence tier: medium. Use the evidence score on this page as a directional read, not a substitute for systematic reviews for your specific question.
Safety
Cautions (registry notes): Same Bacopa tolerability patterns; 4–6 week build-up often noted. Always disclose supplements to clinicians when pregnant, breastfeeding, on anticoagulants, or managing diabetes, thyroid, seizure, or transplant medications.
300-320 mg in some studies (typical supplement-label context, not individualized dosing).
Product-level dosing varies. This section is general context, not a prescription.
Shorter pages tuned to how people ask - each links back here for the full file.
A few hand-picked entry points around Synapsa (Bacopa CDRI-08): categories, answers to narrow questions, and comparisons.
Grouped near Synapsa (Bacopa CDRI-08) in the model - not interchangeable.
Occasional constipation; Detox teas (problematic chronic use). Typical label framing: OTC protocols short term; chronic misuse harmful.
Rhizome with decent human trials for pregnancy-related nausea and some pain contexts; culinary doses are broadly safe.
An adaptogen with promising stress and sleep trials, but heterogeneity, product quality, and thyroid interactions require caution.
Swaps discussed alongside Synapsa (Bacopa CDRI-08) - judge each on its own evidence.
No sponsored reviews
Editorial model. No paid verdicts.
Evidence-based analysis
Human trial signal, not storefront copy.
Continuously updated
Hubs revised as synthesis changes.
Scores compress ingredient evidence, dosage discussion, claim stress-testing, and hype gap. Outbound retailer links do not change the model output.
· ·